Covid19

Early Promise for PCSK9 Inhibition in Severe COVID-19 | MedPage Today

Among people with severe COVID-19 with respiratory failure and heightened inflammation, the advantage of getting PCSK9 inhibition therapy was a …

Read more at www.medpagetoday.com

Show More

Related Articles

Back to top button